13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001442756
Total reported value
$1.2B
$1.2B
84 檔
49.6%
During the Q1 2024 filing period, PFM Health Sciences, LP (CIK: 0001442756) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.2B across 84 reported positions.
During Q1 2024, PFM Health Sciences, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 10.92% | -1.48% | — | |
| 2 | CYTK | Cytokinetics Inc | Stock-Healthcare | 5.79% | +1.40% | NEW | |
| 3 | MRK | Merck & Co. Inc. | Stock-Healthcare | 3.70% | +1.40% | NEW | |
| 4 | ABBV | Abbvie Inc | Stock-Healthcare | 3.46% | — | -0.77% | |
| 5 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 3.33% | +0.08% | — | |
| 6 | HCA | Hca Healthcare Inc | Stock-Healthcare | 3.08% | -0.49% | +57.51% | |
| 7 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.92% | — | — | |
| 8 | THC | Tenet Healthcare CORP | Stock-Healthcare | 2.91% | -4.83% | — | |
| 9 | MCK | Mckesson CORP | Stock-Healthcare | 2.46% | — | — | |
| 10 | TLT | Ishares 20+ Year Treasury Bd | ETF-Gov Bonds | 2.33% | — | — | |
| 11 | CNC | Centene CORP | Stock-Healthcare | 2.21% | +1.07% | +7.31% | |
| 12 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.08% | — | +356.81% | |
| 13 | HUM | Humana Inc | Stock-Healthcare | 2.04% | +3.22% | NEW | |
| 14 | BDX | Becton Dickinson And Co | Stock-Healthcare | 2.00% | — | -14.24% | |
| 15 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.94% | — | +8.13% | |
| 16 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 1.86% | — | +166.61% | |
| 17 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 1.86% | — | — | |
| 18 | UHS | Universal Health Services-b | Stock-Healthcare | 1.84% | — | +5.78% | |
| 19 | ICLR | ICON Public Limited Company | Stock-Healthcare | 1.83% | +1.45% | +13.67% | |
| 20 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.75% | +0.54% | — | |
| 21 | PEN | Penumbra Inc | Stock-Healthcare | 1.63% | -2.56% | — | |
| 22 | AVTR | Avantor Inc | Stock-Healthcare | 1.61% | — | +98.50% | |
| 23 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.61% | +0.06% | — | |
| 24 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.59% | +0.57% | +13.07% | |
| 25 | CRBU | Caribou Biosciences Inc | Stock-Other | 1.57% | -0.12% | +0.04% | |
| 26 | DHR | Danaher CORP | Stock-Healthcare | 1.47% | — | — | |
| 27 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.37% | +0.07% | -27.26% | |
| 28 | MOH | Molina Healthcare Inc | Stock-Healthcare | 1.35% | — | — | |
| 29 | ELV | Elevance Health Inc | Stock-Healthcare | 1.35% | — | +15.87% | |
| 30 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 1.33% | — | — | |
| 31 | FXI | Ishares China Large-cap ETF | ETF-Emerging Markets | 1.32% | — | — | |
| 32 | VEEV | Veeva Systems Inc-class A | Stock-Healthcare | 1.30% | — | — | |
| 33 | EPIEUR | Essa Pharma Inc | Stock-Other | 1.19% | — | -8.65% | |
| 34 | DXCM | Dexcom Inc | Stock-Healthcare | 1.02% | -0.86% | EXIT | |
| 35 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 1.00% | +0.09% | -13.06% | |
| 36 | ACLXGBX | Arcellx Inc | Stock-Other | 0.99% | — | -9.54% | |
| 37 | WST | West Pharmaceutical Services | Stock-Healthcare | 0.95% | +0.64% | NEW | |
| 38 | SYK | Stryker CORP | Stock-Healthcare | 0.93% | +0.87% | -6.03% | |
| 39 | HOWL | Werewolf Therapeutics Inc | Stock-Other | 0.92% | — | -13.31% | |
| 40 | NVRO 2.75 04-01-25Bond | Nevro CORP | Bond | 0.78% | — | — | |
| 41 | ADAPY | Adaptimmune Therapeutics-adr | Stock-Other | 0.77% | — | — | |
| 42 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.74% | -0.30% | +10.61% | |
| 43 | IMVT | Immunovant Inc | Stock-Other | 0.72% | — | — | |
| 44 | BMRN 0.599 08-01-24Bond | Biomarin Pharmaceutical | Bond | 0.69% | — | — | |
| 45 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 0.63% | — | — | |
| 46 | WAT | Waters CORP | Stock-Healthcare | 0.62% | +0.85% | — | |
| 47 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.60% | +0.75% | +156.07% | |
| 48 | ARKK | Ark Innovation ETF | ETF-Other | 0.57% | — | — | |
| 49 | BSX | Boston Scientific CORP | Stock-Healthcare | 0.56% | — | -27.44% | |
| 50 | ALKS | Alkermes plc | Stock-Healthcare | 0.55% | — | — |
According to official SEC Form 13F filings, PFM Health Sciences, LP reported a total U.S. public equity portfolio value of $1.2B across 84 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, CYTK, MRK) accounted for 49.6% of total reported equity market value during Q1 2024.
During Q1 2024, PFM Health Sciences, LP's top holdings by market value included LLY (10.9%)、CYTK (5.8%)、MRK (3.7%). The largest single position, LLY, represented 10.9% of total portfolio value.
In Q1 2024, PFM Health Sciences, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.